What is BDD Pharma?
BDD Pharma specializes in biopharmaceutics, oral drug formulation, and Phase 1 clinical trials, leveraging over 25 years of experience to offer a streamlined approach to early-stage drug development. Their proprietary Lean Clinical Development methodology is designed to accelerate timelines and reduce costs for pharmaceutical clients. The company provides comprehensive services including formulation development, GMP manufacturing, and integrated clinical trial support, positioning itself as a key partner for companies navigating the complexities of bringing new therapies to market. BDD Pharma emphasizes a personal and collaborative approach to deliver tailored solutions.
How much funding has BDD Pharma raised?
BDD Pharma has raised a total of $2.5M across 1 funding round:
Other Financing Round
$2.5M
Other Financing Round (2023): $2.5M with participation from Archangels, Scottish Enterprise, and British Business Bank
Key Investors in BDD Pharma
Archangels
Archangels is an established entity providing comprehensive architectural services, suggesting a strategic interest in well-structured and long-term ventures, potentially aligning with BDD Pharma's focus on structured drug development.
Scottish Enterprise
Scottish Enterprise is a government-backed organization that supports businesses in Scotland, indicating a potential focus on fostering innovation and economic growth within the region's life sciences sector.
British Business Bank
The British Business Bank is a government-owned financial institution that aims to increase the supply of credit to small and medium enterprises, suggesting a role in supporting BDD Pharma's growth and operational scaling.
What's next for BDD Pharma?
With a recent major strategic investment, BDD Pharma is poised for accelerated growth and expansion of its service offerings. The substantial capital infusion is expected to bolster its capabilities in biopharmaceutics and oral drug formulation, potentially enabling the company to take on larger-scale projects and further refine its Lean Clinical Development process. This strategic backing suggests a focus on scaling operations, enhancing technological infrastructure, and potentially broadening its market reach within the pharmaceutical and biotechnology industries. The company's commitment to personalized client solutions will likely remain a cornerstone as it navigates this next phase of development.
See full BDD Pharma company page
